inflammation on bone, hematopoietic and erythropoietic maintenance and agents that affect these macrophages, such as G-CSF, are likely to affect these three processes concomitantly.
Introduction
Erythropoiesis, the processes leading to the formation of blood erythrocytes, is a highly active, life sustaining processes. Blood erythrocytes have a life span of 100-120 days and as such, a typical adult must produce 2.5 million erythrocytes per second to replace them.
Erythropoiesis involves the differentiation of hematopoietic stem cells (HSCs) into myeloiderythroid progenitors in the bone marrow (BM), which further commit to the erythroid lineage throughout the generation of proerythroblasts and erythroblasts. After synthesizing large quantities of hemoglobin, the final stages of erythroblast maturation involves extrusion of the nucleus to form anuclear reticulocytes, which then change shape in the blood to fully matured erythrocytes. Microscopy sections of BM have revealed that maturing erythroblasts rosette around a central macrophage to form erythroid islands [1] [2] [3] [4] [5] . It has been proposed that these erythroid island macrophages contribute to the efficient transport of iron to erythroblasts [2, 6] enabling the synthesis of large quantities of hemoglobin as O 2 and CO 2 transport which depends on Fe 2+ complexed in the heme molecule. These "nursing" macrophages at the center of erythropoietic islands have also been proposed to secrete cytokines essential to erythroblast survival and maintenance such as insulin-like growth factor 1 [7, 8] . Finally erythroid island macrophages phagocytose and degrade erythroblast nuclei during nuclear extrusion, a step necessary to generate anucleated reticulocytes [9, 10] .
While these macrophages are essential for erythropoiesis, little work has been done on their phenotypic identification so they can be studied further, particularly in disease states where erythropoiesis is perturbed such as myelodysplastic syndrome, chronic and acute myeloid leukemia, and chronic inflammation.
Systemic administration of granulocyte-colony stimulating factor (G-CSF) mobilizes
HSC from the BM into the blood in order to harvest large quantities of HSC for subsequent transplantation in humans. G-CSF causes HSC mobilization by perturbing HSC niches in the BM [11, 12] . This results in the down-regulation of cell adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and the chemokine CXC-motif ligand-12 (CXCL12), which are both essential to HSC retention within the BM [13] [14] [15] [16] . Furthermore it has been recently demonstrated that this effect of G-CSF on HSC niches is mediated in part by a subset of BM macrophages [15] [16] [17] . In the mouse HSC niche supportive macrophages express the macrophage-specific antigen F4/80 together with the Ly-6G granulocyte antigen [16, 18] . A separate report suggests that HSC niche supportive macrophages express CD169 also called M A N U S C R I P T
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4 sialic acid binding immunoglobulin-like lectin 1 (Siglec-1) or sialoadhesin [15] . However whether F4/80 + Ly-6G + macrophages express CD169 has never been reported. G-CSF treatment depletes F4/80 + Ly-6G + macrophages in the BM [16, 18] , resulting in a concomitant loss of osteoblasts and bone formation, decreased expression of VCAM-1 and CXCL12, and HSC mobilization [15] [16] [17] . In support of this notion, three independent models of macrophage depletion result in HSPC mobilization in the mouse: 1) in macrophage Fas-induced apoptosis (MAFIA) transgenic mice, 2) by injection of clodronate-loaded liposomes into wild-type mice, or 3) following selective depletion of CD169 + macrophages in Siglec1 DTR/+ mice [15, 16] . Considering that macrophages are important regulators of both HSC niches and erythropoiesis, we explored the effect of mobilizing doses of G-CSF on erythropoiesis and erythroid island macrophages.
Materials and Methods

Mice and treatments
All procedures had been approved by the Animal Experimentation Ethics Committee of the University of Queensland.
C57BL/6 mice were purchased from the Animal Resource Centre (Perth, Australia).
Siglec1
DTR/DTR mice were obtained from the Riken Bio Resource Centre (Japan) and were bred with wild-type C57BL/6 females to generate Siglec1 DTR/+ mice for experimentations. [19] .
All experimentations were performed on 8-10 week old male mice. Mice were injected twice daily subcutaneously with 125µg/kg per injection recombinant human G-CSF (Neupogen, Amgen Thousand Oaks, CA) diluted in saline for injection or saline for up to 4 consecutive days.
For macrophage depletion, dichloromethylene bisphosphonate (clodronate, Roche Diagnostics, Mannheim, Germany) was packaged into liposomes as previously described [20] . Empty liposomes were prepared in the same conditions in PBS without clodronate.
Phagocytic macrophages were depleted in vivo by retro-orbitally injecting 200µL/20g body M A N U S C R I P T A C C E P T E D HR3 antibody, and streptavidin-PE. Cell aggregates were gated as the tail of the forward scatter pulse width to detect erythroid islands [21] .
In all stains, 5µg/mL 7-amino actinomycin D was added 15 minutes prior to acquisition to exclude dead leukocytes. Data were acquired on a CyAn (Dako Cytomation) flow cytometer and analyzed following compensation with single color controls using FloJo software (Tree Star, Ashland, OR). For sorting, cells were sorted on a FACS Aria cell sorter (BD Biosciences).
All antibodies were purchased from Biolegend except ER-HR3 and CD169 antibodies which were purchased from AbD Serotec.
Immunohistochemistry
Spleens and hind limb bones were fixed in PBS with 4% paraformalhehyde for 4 hours and 24 hours at 4°C respectively. Following bone decalcification, tissues were embedded in paraffin and 4-5 µm sections cut and placed on SuperFrost Plus® slides (Menzel, Germany).
Sections were deparaffinized and re-hydrated with xylene and graded ethanol and washed in
Tris-buffered saline. After antigen retrieval with trypsin a section from each sample was stained with unconjugated rat anti-ER-HR3. This was then detected using a two-step procedure as pervious described [22] . Consecutive sections from each sample were stained with biotinylated rat anti-Ter119 without antigen retrieval. Primary antibody was detected with horseradish peroxidase conjugated streptavidin (Dako, Glostrup, Denmark) and diaminobenzidine (DAB) chromogen. Sections were counterstained with Hematoxylin.
Double staining was undertaken with the first stage replicating the procedure for anti-ER-HR3 single staining. Prior to DAB development, sections were incubated with antiTer119-biotinylated antibody which was subsequently detected using a Vectorstain ABCalkaline phosphatase kit (Vector Laboratories, Burlingame, CA). ER-HR3 expression was detected by DAB chromogen development and Ter119 expression by liquid permanent red (Dako). Double stained sections were counterstained with methyl green.
Specificity of staining was confirmed by comparison to serial sections stained with isotype matched control antibody. All sections were examined using an Olympus BX-51 microscope with a DP-70 digital camera and DP controller imaging software (Olympus). 
RNA extraction and qRT-PCR
Statistical analyses
All data are presented as average ± SD. Statistical differences were calculated with a Student's t-test.
Results
G-CSF treatment causes BM anemia
The first indication G-CSF treatment was interfering with erythropoiesis was a marked whitening of the BM flushed from C57BL/6 mice mobilized for 2 to 6 days with G-CSF compared to BM flushed from saline-treated control mice (Fig. 1A) . To further examine this,
we stained BM cells with 7-amino actinomycin D to exclude dead leukocytes, Hoechst33342
(Ho) to distinguish nucleated leukocytes and erythroblasts from enucleated reticulocytes and erythrocytes, and antibodies specific for the erythroid lineage marker Ter119 and transferrin receptor CD71 to separate maturational stages of erythroid differentiation [23, 24] .
A 4 day G-CSF treatment, which mobilizes HSC into the blood, reduced the number of according to decreasing CD44 expression and forward scatter [25, 26] . This staining and gating strategy confirmed the marked reduction in all differentiation stages of erythroblasts, In order to determine whether the effect of G-CSF on macrophages was directly mediated via the G-CSF receptor, we sorted from the BM of untreated mice F4/80 + VCAM- showed that G-CSF receptor mRNA (Csf3r) was abundantly expressed by these macrophages, whereas it was absent in IgM + and IgM -B cells (Fig. 2E ). This result suggests that G-CSF may act directly on erythroid island macrophages as they express its cognate receptor.
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G-CSF treatment does not arrest splenic erythropoiesis
In contrast to the BM, G-CSF treatment significantly increased pro-erythroblasts, all populations of erythroblasts and reticulocytes in the spleen (Fig. 3A-B) , thereby explaining why the blood anemia is mild (Fig. 1 D) (Fig. 3E) .
Medullar erythropoiesis restarts after cessation of G-CSF
As G-CSF is administered daily for 5-6 days in human donors, and has been shown to induce a slight (5-10%) but significant reduction in peripheral red blood cells [31] , we next measured the recovery of erythropoiesis following cessation of G-CSF treatment. In mouse BM, the number of erythroblasts did not recover before day 5-7 following cessation of a 4 day course of G-CSF administration (Fig. 4A) . In respect to pro-erythroblasts, their excessive number sharply decreased, between 24 hours and day 3 following G-CSF cessation and remained approximately half of their normal number until day 7 after G-CSF cessation.
In respect to the spleen, erythropoiesis remained elevated and normalization was more protracted than in the BM with a slow decrease in pro-erythroblasts and erythroblast numbers during the 7 days following cessation of G-CSF (Fig. 4C ). This may explain why the blood concentration on hemoglobin decreased only slightly after a 4 day course of G-CSF (Fig. 4 D).
In respect to BM macrophages, the number of F4/80 + VCAM-1 + ER-HR3 + CD169 + Ly-6G + , which were sharply suppressed after 4 days G-CSF, recovered by approximately 50%
24 hours after cessation of G-CSF. However complete recovery to steady-state levels was delayed as their number was still significantly decreased 7 days after G-CSF cessation (Fig.   4B ). This suggests that a portion of BM erythroid island macrophages are restored as early as 24 hours following G-CSF treatment, which may kick-start differentiation of proerythroblasts into erythroblasts and reticulocytes in the BM. However complete normalization requires more than 7 days after cessation of G-CSF.
Macrophage depletion with clodronate-loaded liposomes blocks erythropoiesis in both BM and spleen
To (Fig. 5C ).
In respect to the erythroid linage, clodronate liposome treatment also decreased the red coloration of BM flushes (Fig. 1A) Fig. 5A and 5B). Similar to G-CSF treatment, Ter119 low CD71 + Kit -Ho + pro-erythroblasts were increased 3.6-fold by clodronate liposomes (Fig. 5A and 5B). This suggests that similar to G- Figure 4) .
Therefore, unlike G-CSF, non-selective depletion of phagocytes by clodronate liposomes impairs erythropoiesis in both BM and spleen. Fig. 6A-B ).
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Similar to G-CSF and clodronate liposomes in wild-type mice, DPT treatment in 
Discussion
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Amongst differentiated cells of the body, macrophages are the most functionally plastic [32, 33] . They can fulfill a large number of functions in innate immunity (e.g. phagocytosis of pathogens and dead cells), regulation of adaptive immunity [34] , tissue development, maintenance and repair [35, 36] . Macrophages also play an essential role in pathogenesis caused by excessive inflammatory responses, and in various stages of cancer development [37, 38] such as the initial smoldering inflammation leading to malignant transformation, tumor-associated neo-angiogenesis [39] , metastasis [40, 41] , immune suppression [42] and response to treatment [43] . Although macrophage populations and function have been extensively studied in these solid tissues, paradoxically relatively little is known of macrophage populations and function in the BM.
We and others have recently reported that specific subsets of BM macrophages are critical to the maintenance of osteoblasts and bone formation at the endosteum [16, 22] , and of HSC niches in the mouse [16] . Indeed depletion of macrophages stops bone formation and induces HSC mobilization into the blood [16] . A subset of BM macrophages has also been This effect was unique to the BM as splenic erythropoiesis was not inhibited but increased by G-CSF treatment. [16, 18] . Therefore, the Ly-6G antigen is not exclusively specific of granulocytes as it is also expressed by a subset of macrophages that support erythroblasts (herein) and HSCs [16] in the BM.
Whist others have studied these erythropoietic island macrophages using only one or two antigens, we have examined the expression of a number of antigens at once, allowing for a more precise identification of the erythropoietic island macrophages. This will enable further studies on these macrophages in steady-state as well as in disease states. Anemia is one of the first symptoms associated with a number of hematological malignancies, including chronic and acute myeloid leukemia, and myelodysplastic syndrome. The possibility that erythropoietic island macrophages may be involved or perturbed in the initial stages of these diseases has not been investigated because of the lack of precise markers for these macrophages.
In respect to the function of these macrophage antigens in regulating erythropoiesis, we noticed that Siglec1 DTR/DTR mice, which are functionally knocked-out for the Siglec1 gene and CD169 expression, have normal numbers of pro-erythroblasts, erythroblasts and reticulocytes in their BM (data not shown). Therefore the CD169 antigen, whilst useful to identify or target erythroblast supportive macrophages, is functionally dispensable for erythroblast maturation.
We confirmed that the ER-HR3 antigen, which identifies erythroid islands in spleen and liver
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15 [5, 27, 28] , also identifies erythroid island macrophages in the BM. However, the exact identity of this antigen and whether its expression is necessary to support erythropoiesis remain unknown [44] . On the other hand, it is well established that within the BM hematopoietic compartment, VCAM-1 is mainly expressed by macrophages [30] , and mediates adhesion of erythroblasts to erythroid island macrophages via integrin α4β1
expressed by erythroblasts [45, 46] . Furthermore conditional deletion of the Vcam1 or Itga4 gene in mice impairs erythropoietic recovery following cytotoxic or phenylhydrazine challenge [29, 30] , whereas administration of function-blocking anti-VCAM-1 antibody impairs erythropoietic recovery following BM transplantation [21] .
Although the BM is the main site of erythropoiesis in adults in steady-state, the spleen and liver can become important extramedullary erythropoietic organs when the BM is compromised as observed in some hematological neoplasms [28, 47] . In conclusion, G-CSF doses used to mobilize HSCs in transplantation donors transiently impair the function of different subsets of tissue supportive macrophages in the mouse BM particularly osteomacs that support bone forming osteoblasts [22, 50] , HSC nichesupportive macrophages [15] [16] [17] and erythropoietic island macrophages (herein). This further demonstrates that macrophages are potent relays of innate immunity and inflammation on i) osteogenic, ii) hematopoietic and iii) erythropoietic processes in the BM and that treatments or agents that affect these macrophages, are likely to affect these three processes concomitantly [12] . 
